MCID: HMN021
MIFTS: 51

Human T-Cell Leukemia Virus Type 1 malady

Categories: Rare diseases, Immune diseases, Cancer diseases, Skin diseases, Blood diseases

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

About this section

Aliases & Descriptions for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 48
Human T Lymphotropic Virus Type 1 48
 
Htlv-1 48

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

About this section
NIH Rare Diseases:48 Human T-cell leukemia virus, type 1 (HTLV-1) is a retroviral infection that affect the T cells (a type of white blood cell). Although this virus generally causes no signs or symptoms, some affected people may later develop adult T-cell leukemia (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It can also be spread from mother to child during birth or breast-feeding. There is no cure or treatment for HTLV-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life. Last updated: 12/10/2014

MalaCards based summary: Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to htlv-1 associated myelopathy/tropical spastic paraparesis and infective dermatitis associated with htlv-1. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways are Serotonin Receptor 4/6/7 and NR3C Signaling and Atypical NF-kappaB pathway. Affiliated tissues include t cells, bone and bone marrow, and related mouse phenotypes are Decreased Hepatitis C Virus pseudoparticles (HCVpp and craniofacial.

Wikipedia:71 Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the... more...

Related Diseases for Human T-Cell Leukemia Virus Type 1

About this section

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
human t-cell leukemia virus type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
idRelated DiseaseScoreTop Affiliating Genes
1htlv-1 associated myelopathy/tropical spastic paraparesis11.3
2infective dermatitis associated with htlv-111.3
3leukemia11.2
4t-cell leukemia11.2
5adult t-cell leukemia10.5
6sinding-larsen-johansson disease10.4ATF1, CREB1
7lymphoma10.4
8chromosome 16p13.3 duplication syndrome10.3CREB1, CREBBP, EP300
9tropical spastic paraparesis10.2
10spastic paraparesis10.2
11spasticity10.2
12hiv-110.1
13hepatitis c virus10.0
14hepatitis10.0
15hepatitis c10.0
16intracranial structure hemangioma10.0CREB1, CREBBP, GLI2
17intracranial cysts10.0CREB1, CREBBP, EP300, JUN
18rectum leiomyoma9.9CNTN2, CRTC2, GLI2
19rheumatoid arthritis9.9
20lung cancer9.9
21retinoblastoma9.9
22arthritis9.9
23chronic lymphocytic leukemia9.9
24t-cell large granular lymphocyte leukemia9.9
25gastric lymphoma9.9
26graves' disease9.9
27uveitis9.9
28arthropathy9.9
29borna disease9.9
30neuronitis9.9
31herpes simplex9.9
32glioblastoma9.9
33large granular lymphocyte leukemia9.9
34pituitary tumors9.9
35endotheliitis9.9
36parainfluenza virus type 39.9CNTN2, CREB1, CREBBP, EP300, NFKB1
37osteogenesis imperfecta9.9CDK4, CREBBP
38leukemia, acute myeloid9.6CDKN1A, CREBBP, EP300, JUN
39clear cell sarcoma9.6ATF1, CDK4, CREB1
40myotubular myopathy, x-linked9.3CDK2, CDK4, CDKN1A
41bilateral retinoblastoma9.3CDK2, CDK4, CDKN1A
42pharynx cancer9.3CDK2, CDK4, CDKN1A
43ascending colon cancer9.2CDK2, CDK4, CDKN1A
44stenosis of lacrimal sac9.2CDK2, CDK4, CDKN1A
45gliosarcoma9.1CDK2, CDK4, CDKN1A
46gliomatosis peritonei8.8CDK2, CDK4, CDKN1A
47prostate cancer7.5CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
48human t-cell leukemia virus type 37.3ATF1, CDKN1A, CHUK, CNTN2, CREB1, CREBBP

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to human t-cell leukemia virus type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

About this section

GenomeRNAi Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00234-A-18.7CDK2, CDK4, CHUK, IKBKB

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

41 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.4CDKN1A, CHUK, CREBBP, EP300, GLI2, NFKB1
2MP:00053888.0CDKN1A, CHUK, CREB1, CREBBP, EP300, GLI2
3MP:00028738.0CDK4, CREB1, CREBBP, EP300, GLI2, IKBKB
4MP:00020067.9CDK2, CDK4, CDKN1A, CHUK, CREBBP, EP300
5MP:00053717.8CDKN1A, CHUK, CNTN2, CREBBP, CRTC3, GLI2
6MP:00053907.6CDKN1A, CHUK, CREB1, CREBBP, CRTC3, GLI2
7MP:00053917.5CDK2, CDK4, CDKN1A, CHUK, EP300, GLI2
8MP:00053817.1CDK4, CDKN1A, CHUK, CREBBP, EP300, GLI2
9MP:00053697.0CDK2, CDK4, CDKN1A, CREB1, CREBBP, CRTC3
10MP:00107716.8CDK2, CDK4, CDKN1A, CHUK, CREBBP, GLI2
11MP:00053876.7CDK2, CDK4, CDKN1A, CHUK, CREBBP, EP300
12MP:00053806.7CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
13MP:00053976.7CDK2, CDK4, CDKN1A, CHUK, CREBBP, EP300
14MP:00053706.4CDK2, CDK4, CDKN1A, CHUK, CREBBP, CRTC2
15MP:00053796.4CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
16MP:00036316.3CDK4, CDKN1A, CHUK, CNTN2, CREB1, CREBBP
17MP:00053856.3CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
18MP:00053845.8CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
19MP:00107685.6CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
20MP:00053785.5CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP
21MP:00053765.1CDK2, CDK4, CDKN1A, CHUK, CREB1, CREBBP

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

About this section

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 202)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Daclizumabapproved, investigationalPhase 4, Phase 1, Phase 298152923-56-3
Synonyms:
 
Dacliximab
Daclizumab beta
2AntibodiesPhase 4, Phase 2, Phase 16045
3ImmunoglobulinsPhase 4, Phase 2, Phase 16045
4Immunosuppressive AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112770
5Immunoglobulin GPhase 4, Phase 1, Phase 2265
6
ZidovudineapprovedPhase 2, Phase 3, Phase 1, Early Phase 149430516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
 
CPD000058351
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
7
Pentoxifyllineapproved, investigationalPhase 3996493-05-64740
Synonyms:
1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion
1-(5-Oxohexyl)-3,7-dimethylxanthine
1-(5-Oxohexyl)theobromine
2a3c
3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl) xantine
3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione
3,7-Dimethyl-1-(5-oxohexyl)xanthine
3,7-Dimethyl-1-(5-oxohexyl)xantine
3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione
5-26-14-00081 (Beilstein Handbook Reference)
6493-05-6
AB00052363
AC1L1IUN
AKOS000541484
Agapurin
Agapurin Retard
Azupentat
BAS 00897429
BB_SC-2111
BIDD:GT0174
BL 191
BL-191
BL191
BPBio1_000167
BRD-K57569181-001-05-1
BRN 0558929
BSPBio_000151
BSPBio_003439
C07424
C13H18N4O3
CAS-1677687
CCRIS 6832
CHEMBL628
CID4740
CPD000035998
D00501
D010431
DB00806
Dimethyloxohexylxanthine
DivK1c_000729
Durapental
EHT 0201
EHT-0201
EHT-201
EHT0201
EINECS 229-374-5
EU-0100936
HMS1568H13
HMS1922E16
HMS2051N06
HMS2090H13
HMS2093G21
HMS502E11
Hemovas
I06-1592
IDI1_000729
IN1161
Ikomio
KBio1_000729
KBio2_001924
KBio2_004492
KBio2_007060
KBio3_002942
KBioGR_000893
KBioSS_001924
LS-149385
 
Lopac-P-1784
Lopac0_000936
MLS000079026
MLS000758298
MLS001201764
MolPort-001-823-263
NCGC00015801-01
NCGC00015801-02
NCGC00015801-04
NCGC00015801-10
NCGC00067069-02
NCGC00067069-03
NCGC00067069-04
NCGC00067069-05
NCGC00178062-01
NCGC00178062-02
NINDS_000729
NSC 637086
NSC637086
Oxpentifylline
P 1784
PDSP1_001015
PDSP2_000999
PENTOXYPHYLINE
PNX
Pentoxifilina
Pentoxifilina [INN-Spanish]
Pentoxifyllin
Pentoxifylline
Pentoxifylline (JAN/USP/INN)
Pentoxifylline [USAN:INN:JAN]
Pentoxifyllinum
Pentoxifyllinum [INN-Latin]
Pentoxil
Pentoxil (TN)
Pentoxiphyllin
Pentoxiphylline
Pentoxiphyllium
Pentoxyfylline
Pentoxyphyllin
Pentoxyphylline
Prestwick0_000196
Prestwick1_000196
Prestwick2_000196
Prestwick3_000196
Prestwick_608
Px
Ralofect
Rentylin
SAM001247011
SMR000035998
SPBio_001221
SPBio_002072
SPECTRUM1503611
SR-01000075641-4
STK177321
Spectrum2_001181
Spectrum3_001820
Spectrum4_000227
Spectrum5_001161
Spectrum_001444
Torental
Trental
Trental (TN)
UNII-SD6QCT3TSU
Vasofirin
Vazofirin
ZINC01530776
cis-9-Octadecenoyl coenzyme A
pentoxifylline
8
Valproic Acidapproved, investigationalPhase 3, Phase 1, Phase 232299-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
9
Lamivudineapproved, investigationalPhase 2, Phase 3613134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
 
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine
10
Cyclosporineapproved, investigational, vet_approvedPhase 2, Phase 3, Phase 191579217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
11
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 3, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
12
LopinavirapprovedPhase 2, Phase 3342192725-17-092727
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
A 157378
A 157378.0
A-157378-0
A-157378.0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
AC1L3OPJ
AIDS032937
 
Aluviran
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Koletra
LPV
LS-173766
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
13
Ritonavirapproved, investigationalPhase 2, Phase 3870155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
14AnticonvulsantsPhase 3, Phase 1, Phase 22620
15Calcineurin InhibitorsPhase 2, Phase 3, Phase 11597
16AntimetabolitesPhase 2, Phase 3, Phase 1, Early Phase 111774
17Anti-Infective AgentsPhase 2, Phase 3, Phase 1, Early Phase 121402
18Integrase InhibitorsPhase 2, Phase 3, Phase 1, Early Phase 1408
19Anti-HIV AgentsPhase 2, Phase 3, Phase 1, Early Phase 13100
20Raltegravir PotassiumPhase 2, Phase 3, Phase 1, Early Phase 1291
21Antirheumatic AgentsPhase 2, Phase 3, Phase 1, Early Phase 110627
22HIV Integrase InhibitorsPhase 2, Phase 3, Phase 1, Early Phase 1387
23Neurotransmitter AgentsPhase 3, Phase 1, Phase 217734
24Anti-Retroviral AgentsPhase 2, Phase 3, Phase 1, Early Phase 13232
25Antiviral AgentsPhase 2, Phase 3, Phase 1, Early Phase 19732
26Protective AgentsPhase 3, Phase 27190
27HIV Protease InhibitorsPhase 2, Phase 35319
28Antifungal AgentsPhase 2, Phase 3, Phase 13615
29Phosphodiesterase InhibitorsPhase 31254
30
protease inhibitorsPhase 2, Phase 35320
Synonyms:
 
protease inhibitors
31Reverse Transcriptase InhibitorsPhase 2, Phase 3, Phase 1, Early Phase 11880
32AntioxidantsPhase 32928
33Tranquilizing AgentsPhase 3, Phase 1, Phase 24164
34Platelet Aggregation InhibitorsPhase 32419
35Antimanic AgentsPhase 3, Phase 1, Phase 2790
36Radiation-Protective AgentsPhase 3466
37Psychotropic DrugsPhase 3, Phase 1, Phase 26279
38Vasodilator AgentsPhase 33438
39Central Nervous System DepressantsPhase 3, Phase 1, Phase 212806
40Dermatologic AgentsPhase 2, Phase 3, Phase 15674
41GABA AgentsPhase 3, Phase 1, Phase 21622
42Nucleic Acid Synthesis InhibitorsPhase 2, Phase 3, Phase 1, Early Phase 14855
43Cytochrome P-450 Enzyme InhibitorsPhase 2, Phase 33822
44Cytochrome P-450 CYP3A InhibitorsPhase 2, Phase 31666
45
Tacrolimusapproved, investigationalPhase 21074104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
46
Mycophenolic acidapprovedPhase 2, Phase 193924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
47
Mycophenolate mofetilapproved, investigationalPhase 2, Phase 1939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
48
Doxorubicinapproved, investigationalPhase 2, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
49
Vincristineapproved, investigationalPhase 2, Phase 19042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
50
Prednisoloneapproved, vet_approvedPhase 2, Phase 1115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone

Interventional clinical trials:

(show top 50)    (show all 122)
idNameStatusNCT IDPhase
1Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)CompletedNCT01418430Phase 4
2Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)Unknown statusNCT01343355Phase 2, Phase 3
3Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised TrialCompletedNCT00272480Phase 2, Phase 3
4Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) DiseasesCompletedNCT01472263Phase 3
5Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)CompletedNCT00773292Phase 2, Phase 3
6Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)CompletedNCT00681980Phase 3
7Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV InfectionRecruitingNCT01854762Phase 2, Phase 3
8Trial to Assess Effect of Raltegravir on HTLV-1 Proviral LoadUnknown statusNCT01620736Phase 2
9Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerUnknown statusNCT01044745Phase 2
10Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)CompletedNCT00001785Phase 2
11Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/LymphomaCompletedNCT00041327Phase 2
12Lenalidomide in HTLV-1 Adult T-Cell LeukemiaCompletedNCT01274533Phase 2
13Anti-Tac for Treatment of LeukemiaCompletedNCT00001941Phase 1, Phase 2
14EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia LymphomaCompletedNCT01000285Phase 1, Phase 2
15Campath-1H for Treating Adult T-Cell Leukemia/LymphomaCompletedNCT00061048Phase 2
16Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell LeukemiaCompletedNCT00117845Phase 2
17Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative MalignanciesCompletedNCT00481871Phase 1, Phase 2
18Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone TransplantationCompletedNCT00005606Phase 2
19Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1, Phase 2
20Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2
21Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2
22High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
23Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2
24Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2
25Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00006473Phase 2
26Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2
27Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
28Ruxolitinib for Adult T-Cell LeukemiaRecruitingNCT01712659Phase 2
29Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaRecruitingNCT02631746Phase 2
30Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasRecruitingNCT01805037Phase 1, Phase 2
31Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesRecruitingNCT00002663Phase 1, Phase 2
32Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesRecruitingNCT01760655Phase 2
33Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesRecruitingNCT01839916Phase 2
34Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell LeukemiaActive, not recruitingNCT00924170Phase 1, Phase 2
35Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT00078858Phase 1, Phase 2
36Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaActive, not recruitingNCT01075321Phase 1, Phase 2
37Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaActive, not recruitingNCT00918333Phase 1, Phase 2
38Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerActive, not recruitingNCT00006251Phase 1, Phase 2
39Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerActive, not recruitingNCT00089011Phase 2
40Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerActive, not recruitingNCT00118352Phase 2
41Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesActive, not recruitingNCT01529827Phase 2
42Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesActive, not recruitingNCT00040846Phase 2
43Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaActive, not recruitingNCT01261247Phase 2
44Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal CancerSuspendedNCT01769222Phase 1, Phase 2
45Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/LymphomaTerminatedNCT00854581Phase 1, Phase 2
46The HAM Infliximab StudyTerminatedNCT00823641Phase 2
47Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2
48Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2
49Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid MalignanciesTerminatedNCT00776373Phase 1, Phase 2
50Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

About this section

Anatomical Context for Human T-Cell Leukemia Virus Type 1

About this section

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

36
T cells, Bone, Bone marrow, Liver, B cells, Testes, Brain

Publications for Human T-Cell Leukemia Virus Type 1

About this section

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50)    (show all 441)
idTitleAuthorsYear
1
The Tax-Inducible Actin-Bundling Protein Fascin Is Crucial for Release and Cell-to-Cell Transmission of Human T-Cell Leukemia Virus Type 1 (HTLV-1). (27776189)
2016
2
Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. (27677902)
2016
3
Permissive Sense and Antisense Transcription from the 5' and 3' Long Terminal Repeats of Human T-Cell Leukemia Virus Type 1. (26792732)
2016
4
Human T-cell leukemia virus type 1 (HTLV-1) Tax1 oncoprotein but not HTLV-2 Tax2 induces the expression of OX40 ligand by interacting with p52/p100 and RelB. (26739459)
2016
5
Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis. (26819304)
2016
6
Enhanced Stabilization of MCL1 by the Human T-Cell Leukemia Virus Type 1 bZIP Factor Is Modulated by Blocking the Recruitment of Cullin 1 to the SCF Complex. (27697867)
2016
7
Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan. (26996829)
2016
8
Induction of Cell Death in Growing Human T-Cells and Cell Survival in Resting Cells in Response to the Human T-Cell Leukemia Virus Type 1 Tax. (26829041)
2016
9
Expression of Alternatively Spliced Human T-Cell Leukemia Virus Type 1 mRNAs Is Influenced by Mitosis and by a Novel cis-Acting Regulatory Sequence. (26581997)
2016
10
Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation. (26819312)
2016
11
Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. (26174324)
2015
12
Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography. (25473052)
2015
13
miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection. (25568327)
2015
14
Regulation of the tumor marker Fascin by the viral oncoprotein Tax of human T-cell leukemia virus type 1 (HTLV-1) depends on promoter activation and on a promoter-independent mechanism. (26363219)
2015
15
Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-I_B inhibitor A20 and constitutive NF-I_B signaling. (25774694)
2015
16
Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study. (26292315)
2015
17
Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. (26608313)
2015
18
SIRT1 Suppresses Human T-Cell Leukemia Virus Type 1 Transcription. (26063426)
2015
19
Advanced human T-cell leukemia virus type 1 carriersA and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. (25703103)
2015
20
Prevalence of human T-cell leukemia virus type 1 carrier in Japanese pregnant women in 2013. (25883717)
2015
21
Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. (26324707)
2015
22
Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence. (26198240)
2015
23
Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease. (25889320)
2015
24
Viral Source-Independent High Susceptibility of Dendritic Cells to Human T-Cell Leukemia Virus Type 1 Infection Compared to That of T Lymphocytes. (26269171)
2015
25
Human T-cell leukemia virus type 1 Tax oncoprotein represses the expression of the BCL11B tumor suppressor in T-cells. (25613934)
2015
26
Reevaluation of confirmatory tests for human T-cell leukemia virus Type 1 using a luciferase immunoprecipitation system in blood donors. (25363675)
2014
27
Palmitoylation and p8-mediated human T-cell leukemia virus type 1 transmission. (24284316)
2014
28
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. (24403582)
2014
29
Human T-cell leukemia virus type 1 Tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis. (24352466)
2014
30
Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. (24792037)
2014
31
LKB1 tumor suppressor and salt-inducible kinases negatively regulate human T-cell leukemia virus type 1 transcription. (23577667)
2013
32
HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-I_B activation and HTLV-1 replication. (24109220)
2013
33
Group I p21-activated kinases facilitate Tax-mediated transcriptional activation of the human T-cell leukemia virus type 1 long terminal repeats. (23622267)
2013
34
An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1. (23750452)
2013
35
CD69 overexpression by human T-cell leukemia virus type 1 Tax transactivation. (23507197)
2013
36
Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1. (23033806)
2013
37
Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. (24060211)
2013
38
p53 dysfunction precedes the activation of nuclear factor-I_B during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. (23633516)
2013
39
Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. (24139400)
2013
40
The cellular autophagy pathway modulates human T-cell leukemia virus type 1 replication. (23175371)
2013
41
Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1. (23888327)
2013
42
Failure in activation of the canonical NF-I_B pathway by human T-cell leukemia virus type 1 Tax in non-hematopoietic cell lines. (23791017)
2013
43
Human T-cell leukemia virus type 1 Tax protein interacts with and mislocalizes the PDZ domain protein MAGI-1. (23279616)
2013
44
Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1. (23606621)
2013
45
Molecular study of HBZ and gp21 human T cell leukemia virus type 1 proteins isolated from different clinical profile infected individuals. (23800288)
2013
46
The four and a half LIM family members are novel interactants of the human T-cell leukemia virus type 1 Tax oncoprotein. (23616667)
2013
47
Activation of mTOR by human T-cell leukemia virus type 1 Tax is important for the transformation of mouse T cells to interleukin-2-independent growth. (22010857)
2012
48
Visualizing spatiotemporal dynamics of apoptosis after G1 arrest by human T cell leukemia virus type 1 Tax and insights into gene expression changes using microarray-based gene expression analysis. (22726420)
2012
49
Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3' long terminal repeat. (22696638)
2012
50
Important Roles of Cellular MicroRNA miR-155 in Leukemogenesis by Human T-Cell Leukemia Virus Type 1 Infection. (23762762)
2012

Variations for Human T-Cell Leukemia Virus Type 1

About this section

Expression for genes affiliated with Human T-Cell Leukemia Virus Type 1

About this section
Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for genes affiliated with Human T-Cell Leukemia Virus Type 1

About this section

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50)    (show all 151)
idSuper pathwaysScoreTop Affiliating Genes
19.9ATF1, CREB1
29.7IKBKB, NFKB1
39.7CREBBP, EP300, NFKB1
49.6CREBBP, EP300, JUN
5
Show member pathways
9.6CREBBP, EP300, JUN
6
Show member pathways
9.6CREBBP, EP300, JUN
7
Show member pathways
9.6CREBBP, EP300, JUN
89.6CREB1, JUN, NFKB1
9
Show member pathways
9.6CREB1, JUN, NFKB1
109.6CREB1, JUN, NFKB1
119.6CREB1, JUN, NFKB1
12
Show member pathways
9.6CREBBP, EP300, XPO1
139.6CREBBP, EP300, XPO1
149.6CDKN1A, CREB1, EP300
159.6EP300, JUN, XPO1
169.5CDKN1A, CREBBP, EP300
179.5CDKN1A, CREBBP, EP300
189.5ATF1, CREB1, JUN
199.5ATF1, CREB1, JUN
20
Show member pathways
9.5ATF1, JUN, NFKB1
219.5CREB1, CREBBP, CRTC2, EP300
22
Show member pathways
9.4CDK2, CREBBP, EP300
239.4CREB1, CREBBP, EP300, NFKB1
249.4CREB1, CREBBP, EP300, JUN
259.4CREB1, CREBBP, EP300, JUN
269.4CREBBP, EP300, JUN, NFKB1
279.4CREBBP, EP300, JUN, NFKB1
28
Show member pathways
9.4CREBBP, EP300, JUN, NFKB1
299.3CDK4, CREBBP, EP300
309.3CREBBP, EP300, NFKB1, XPO1
31
Show member pathways
9.3CDK2, CDKN1A, EP300
329.3CDKN1A, CREBBP, EP300, NFKB1
339.3ATF1, CREB1, JUN, NFKB1
34
Show member pathways
9.3ATF1, CREB1, JUN, NFKB1
359.2CDK4, JUN, NFKB1
369.2CDKN1A, CREBBP, EP300, JUN
379.2CHUK, IKBKB
38
Show member pathways
9.1CDK2, CREBBP, EP300, JUN
39
Show member pathways
9.1CDK2, CREB1, JUN, NFKB1
40
Show member pathways
9.1CREB1, CREBBP, EP300, JUN, NFKB1
419.1CREB1, CREBBP, EP300, JUN, NFKB1
42
Show member pathways
9.0CHUK, JUN, NFKB1
43
Show member pathways
9.0CHUK, JUN, NFKB1
449.0CDK4, CREB1, EP300, JUN
459.0CDK2, CDKN1A, CREBBP, EP300
46
Show member pathways
9.0CDKN1A, CHUK, CREB1
47
Show member pathways
9.0CDK2, CDKN1A, CREB1, JUN
489.0CDKN1A, CREB1, CREBBP, EP300, JUN
498.9CDK2, CDK4, CDKN1A
508.9CDK2, CDK4, CDKN1A

GO Terms for genes affiliated with Human T-Cell Leukemia Virus Type 1

About this section

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1CD40 receptor complexGO:003563110.0CHUK, IKBKB
2IkappaB kinase complexGO:000838510.0CHUK, IKBKB
3cyclin-dependent protein kinase holoenzyme complexGO:00003079.7CDK2, CDK4, CDKN1A
4transcription factor complexGO:00056677.9ATF1, CDK2, CDK4, CREB1, CREBBP, EP300
5nucleusGO:00056345.9ATF1, CDK2, CDK4, CDKN1A, CREB1, CREBBP
6nucleoplasmGO:00056545.8ATF1, CDK2, CDK4, CDKN1A, CHUK, CREB1

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1N-terminal peptidyl-lysine acetylationGO:001807610.7CREBBP, EP300
2protein acetylationGO:000647310.7CREBBP, EP300
3positive regulation by host of viral transcriptionGO:004392310.7EP300, JUN
4response to muscle stretchGO:003599410.6JUN, NFKB1
5response to cobalt ionGO:003202510.6ATF1, EP300
6positive regulation of CREB transcription factor activityGO:003279310.5CRTC2, CRTC3
7positive regulation of type I interferon productionGO:003248110.4CREBBP, EP300, NFKB1
8positive regulation of cell sizeGO:004579310.4CDK4, EP300
9positive regulation of DNA replicationGO:004574010.3ATF1, GLI2, JUN
10DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.1CDK2, CDKN1A, EP300
11I-kappaB phosphorylationGO:000725210.0CHUK, IKBKB
12Ras protein signal transductionGO:000726510.0CDK2, CDKN1A, JUN
13positive regulation of fibroblast proliferationGO:00481469.9CDK4, CDKN1A, JUN
14circadian rhythmGO:00076239.8CDK4, CREB1, EP300, JUN
15animal organ regenerationGO:00311009.7CDK2, CDK4, CDKN1A
16G1/S transition of mitotic cell cycleGO:00000829.7CDK2, CDK4, CDKN1A
17cellular response to tumor necrosis factorGO:00713569.7CHUK, IKBKB, NFKB1
18I-kappaB kinase/NF-kappaB signalingGO:00072499.7CHUK, IKBKB, NFKB1
19stress-activated MAPK cascadeGO:00514039.6CHUK, IKBKB, NFKB1
20regulation of cell cycleGO:00517269.6CDK4, CDKN1A, EP300, JUN
21negative regulation of apoptotic processGO:00430669.5CDKN1A, GLI2, IKBKB, JUN, NFKB1
22Fc-epsilon receptor signaling pathwayGO:00380959.4CHUK, IKBKB, JUN, NFKB1
23transcription from RNA polymerase II promoterGO:00063669.3ATF1, CREB1, EP300, GLI2, JUN, NFKB1
24stimulatory C-type lectin receptor signaling pathwayGO:00022239.1CHUK, CREBBP, EP300, IKBKB, NFKB1
25positive regulation of cell proliferationGO:00082849.0CDK2, CDK4, GLI2, IKBKB, JUN
26response to organic substanceGO:00100338.8CDK4, CDKN1A, CHUK, CREB1, JUN
27viral processGO:00160328.6CREB1, CREBBP, CRTC2, CRTC3, EP300, XPO1
28positive regulation of transcription, DNA-templatedGO:00458938.6CDK2, CREB1, CREBBP, EP300, GLI2, IKBKB
29protein phosphorylationGO:00064688.5CDK2, CDK4, CHUK, CREB1, IKBKB
30response to toxic substanceGO:00096368.3CDK2, CDK4, CDKN1A, CHUK, IKBKB
31response to drugGO:00424937.5CDK2, CDK4, CDKN1A, CHUK, CREB1, IKBKB
32positive regulation of transcription from RNA polymerase II promoterGO:00459447.2ATF1, CHUK, CREB1, CREBBP, CRTC2, CRTC3

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 22)
idNameGO IDScoreTop Affiliating Genes
1acetyltransferase activityGO:001640710.8CREBBP, EP300
2peptide N-acetyltransferase activityGO:003421210.8CREBBP, EP300
3peroxisome proliferator activated receptor bindingGO:004297510.8CREBBP, EP300
4cAMP response element bindingGO:003549710.8CREB1, JUN
5regulatory region DNA bindingGO:000097510.7CREB1, NFKB1
6cAMP response element binding protein bindingGO:000814010.6CRTC2, CRTC3
7RNA polymerase II distal enhancer sequence-specific DNA bindingGO:000098010.4CREB1, JUN, NFKB1
8transcription factor activity, RNA polymerase II distal enhancer sequence-specific bindingGO:000370510.3ATF1, CREB1, JUN
9RNA polymerase II activating transcription factor bindingGO:000110210.2CREB1, CREBBP, EP300, JUN
10RNA polymerase II core promoter proximal region sequence-specific DNA bindingGO:000097810.1CREB1, EP300, GLI2, JUN
11IkappaB kinase activityGO:000838410.0CHUK, IKBKB
12transcriptional activator activity, RNA polymerase II transcription factor bindingGO:00011909.9CREB1, JUN
13cyclin bindingGO:00303329.8CDK2, CDK4, CDKN1A
14transcription factor bindingGO:00081349.7CREB1, CREBBP, EP300, JUN, NFKB1
15sequence-specific DNA bindingGO:00435659.7ATF1, CREB1, GLI2, JUN, NFKB1
16chromatin bindingGO:00036829.7CREBBP, CRTC2, EP300, GLI2, JUN, NFKB1
17transcription regulatory region DNA bindingGO:00442129.7CREB1, GLI2, JUN, NFKB1
18transcription factor activity, sequence-specific DNA bindingGO:00037009.3ATF1, CREB1, CREBBP, GLI2, JUN, NFKB1
19protein complex bindingGO:00324039.1ATF1, CDK2, CDK4, CDKN1A, EP300
20protein heterodimerization activityGO:00469829.0ATF1, CHUK, IKBKB, JUN, NFKB1
21protein kinase activityGO:00046728.8CDK2, CDK4, CHUK, IKBKB
22protein bindingGO:00055155.6ATF1, CDK2, CDK4, CDKN1A, CHUK, CNTN2

Sources for Human T-Cell Leukemia Virus Type 1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet